396 – Nicola Duke Technical Analyst Plus ex-fund manager now private investor Jamie Streeter - Vox Markets
Back

396 – Nicola Duke Technical Analyst Plus ex-fund manager now private investor Jamie Streeter

TO LISTEN TO THE PODCAST CLICK THE PLAY BUTTON BELOW

Subscribe to the podcast in iTunes by clicking HERE

ON TODAY’S PODCAST:
396 – Nicola Duke Technical Analyst Plus ex-fund manager now private investor Jamie Streeter
Nicola Duke
Nicola Duke, technical analyst charts:

Randgold Resources RRS
RRS
(click to enlarge)

Shell RDSB
RDSB daily
RDSB monthly (1)
(click to enlarge)

Northcote NCT
NCT

(click to enlarge)

HSBC HSBA
HSBA
(click to enlarge)

Imperial Tobacco IMT
IMT
(click to enlarge)

PLUS
Jamie Streeter

Jamie Streeter ex-fund manager turned private investor and blogger at CompoundIncome.org talks about portfolio management and Interserve IRV

ALSO….. IT’S A ROLLOVER!!!

Sweepstake

Nobody guessed Brent Crude would be exactly $34.74 at midday today so that will be added to $31.10 from last week.

This means $65.84 plus next week’s Brent Crude price could be won by you if you guess the exact price of Brent Crude at midday next Friday. Submissions close at 4:30pm Thursday.

To take part in the Vox Markets Oil Price Sweepstake click here

VOX BANNER LOGO 001

To set up a free account with VOX Markets click here

TODAY’S, “STOCK WITH POTENTIAL”
Penny Stock With Potential
Is suggested by:
Ivyspivey

What’s the name AND ticker symbol (include both please) of the stock with potential?
Motif Bio (MTFB)

What does the company do?
Develops new Antibiotics to overcome drug resistant bacteria.

Would you say this is a short / medium / long term investment?
Short-US listing and peer valuation rerate
Medium-Phase 3 trial and Strategic Partner Interest
Long-2018 Iclaprim Commercialization and $1bn sales per annum.

How many shares does the company have in issue?
108.6m
MTFB Concert Party/AMP hold 39%(April 2916 LockIn)
Institutions have another 55% including Standard Life/Aviva/Invesco
Free Float less than 6%.

What’s current price AND market capitalisation of the company?
Current SP=39.25 and market cap is £43.35m

What revenue and profit /loss does the company generate? (if none see next question)
No present revenue but projected $40bn market by 2020 and $1bn global sales.

How much cash or debt does the company have?
£20 million cash.

List three reasons why you think this company has potential.
1. Main Asset-Iclaprim a novel antibiotic entering phase 3 with Fastrack/QIDP approval entering a huge market( global crisis and massive need for new antibiotics)

2. Great management both commercial and scientific experience of taking multi billion pound company’s to BASDAQ(Celgene) and running global operations(Merck).

3. Peer valuations in US are up to 5 times higher.Company actively seeking US listing strategy.
WE NEED YOU
Do you know of a stock with potential?
If so I want to hear about it.

Please click here to fill in a form and I could be featuring it on tomorrow’s podcast.

Subscribe 001

Would you like to hear a certain company’s CEO on the podcast? If so click here

VOX BANNER LOGO 001

To set up a free account with VOX Markets click here

The post 396 – Nicola Duke Technical Analyst Plus ex-fund manager now private investor Jamie Streeter appeared first on SharePickers.com.